{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:36:08Z","timestamp":1788806168894,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the prevalence of endocrine\/metabolic disorders among pediatric Duchenne muscular dystrophy (DMD) patients and identify individuals who would benefit from the new corticosteroid treatment available, vamorolone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A national pediatric cohort of DMD patients followed at University Children\u2019s Hospital, University Medical Center Ljubljana in June 2025 was included in the study. The presence of endocrine\/metabolic disorders was determined by clinical examination, laboratory data, and imaging at the last annual multidisciplinary evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 patients (average age 11.1, range 4.6-16.7 yrs) were included in the study. Two patients were corticosteroid-naive, the rest treated with deflazacort (average treatment duration 5.4, range 1.1-11.3 yrs). At the time of final follow-up, 90% were diagnosed with an endocrine and\/or metabolic disorder. Short stature was present in 67% of patients, a decline in height standard deviation score (SDS) since the initiation of corticosteroid therapy was observed, -2.37 SDS on average. Based on body composition data (fat % SDS), 57% were classified as obese. Lipid abnormalities were detected in 76% of patients. Insulin resistance (determined by HOMA-IR) was increased in 9.5% of patients; type 2 diabetes was not detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrate a high prevalence of endocrine and metabolic disturbances among patients with DMD. In light of emerging evidence on the potential benefits of vamorolone - particularly regarding bone health and growth - we identified a subgroup of patients most likely to benefit from its use. We propose that ambulatory, non-corticosteroid naive patients with pathological fractures, markedly reduced bone density, short stature, or significant growth deceleration could be considered for the therapeutic transition. Accordingly, we established national clinical criteria to guide individualized therapeutic transitions, aimed at optimizing clinical outcomes and ensuring efficient allocation of healthcare resources.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1697907","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:16Z","timestamp":1764911596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Endocrine and metabolic complications in a national cohort of Slovene children and adolescents with Duchenne muscular dystrophy: real-world criteria for transition to vamorolone therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Son\u010dka","family":"Jazbin\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vr\u0161\u010daj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"\u0160uput Omladi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tita","family":"Butenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Loboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo\u017e","family":"Kotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damjan","family":"Osredkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"B2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.phm.0000184156.98671.d0","article-title":"Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect","volume":"84","author":"Balaban","year":"2005","journal-title":"Am J Phys Med Rehabil"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD003725","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"2016","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2025-0061","article-title":"Pubertal induction therapy in pediatric patients with Duchenne muscular dystrophy","volume":"38","author":"Sodero","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0333F","article-title":"Obesity and endocrine management of the patient with duchenne muscular dystrophy","volume":"142","author":"Weber","year":"2018","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"109689","DOI":"10.1016\/j.steroids.2025.109689","article-title":"Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials","volume":"223","author":"de Vera","year":"2025","journal-title":"Steroids"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and Safety of Vamorolone vs Placebo and Prednisone among Boys with Duchenne Muscular Dystrophy: A Randomized Clinical Trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in duchenne muscular dystrophy: A 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B15","article-title":"Tanner stages","author":"Emmanuel","year":"2025"},{"key":"B16","first-page":"1","article-title":"Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts","volume":"63","author":"Flegal","year":"2013","journal-title":"Natl Health Stat Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"B18","article-title":"Pediatric dyslipidemia","author":"Gujral","year":"2025"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.v2i3.100","article-title":"Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods","volume":"2","author":"Kurto\u011flu","year":"2010","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2024.01.003","article-title":"Diagnosis and management of congenital hypopituitarism in children","volume":"31","author":"Castets","year":"2024","journal-title":"Arch P\u00e9diatrie"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.06.007","article-title":"Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup","volume":"27","author":"Matsumoto","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.jpeds.2013.08.004","article-title":"Patterns of growth in ambulatory males with Duchenne muscular dystrophy","volume":"163","author":"West","year":"2013","journal-title":"J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-021-02158-9","article-title":"Growth pattern trajectories in boys with Duchenne muscular dystrophy","volume":"17","author":"Stimpson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-308654","article-title":"Short stature and pubertal delay in Duchenne muscular dystrophy","volume":"101","author":"Wood","year":"2016","journal-title":"Arch Dis Child"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442472","article-title":"Short stature: a common feature in Duchenne muscular dystrophy","volume":"147","author":"Eiholzer","year":"1988","journal-title":"Eur J Pediatr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/MED.0000000000000456","article-title":"Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy","volume":"26","author":"Ward","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.05.004","article-title":"The impact of deflazacort on puberty in Duchenne muscular dystrophy","volume":"49","author":"Dooley","year":"2013","journal-title":"Pediatr Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1159\/000508290","article-title":"Effect of testosterone treatment for delayed puberty in duchenne muscular dystrophy","volume":"93","author":"Lee","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000000817","article-title":"Vertebral fractures in duchenne muscular dystrophy patients managed with deflazacort","volume":"38","author":"Singh","year":"2018","journal-title":"J Pediatr Orthopaedics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2017.08.006","article-title":"Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy","volume":"12","author":"Saure","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12887-017-0891-z","article-title":"BMI is a poor predictor of adiposity in young overweight and obese children","volume":"17","author":"Vanderwall","year":"2017","journal-title":"BMC Pediatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/mus.26340","article-title":"Body composition and body mass index in Duchenne muscular dystrophy: Role of dietary intake","volume":"59","author":"Bernabe-Garc\u00eda","year":"2019","journal-title":"Muscle Nerve"},{"key":"B34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jacl.2020.05.098","article-title":"High prevalence of plasma lipid abnormalities in human and canine Duchenne and Becker muscular dystrophies depicts a new type of primary genetic dyslipidemia","volume":"14","author":"White","year":"2020","journal-title":"J Clin Lipidol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230064","article-title":"Dyslipidemia in muscular dystrophy: A systematic review and meta-analysis","volume":"10","author":"Sun","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-15-0533","article-title":"Insulin resistance and sarcopenia: mechanistic links between common co-morbidities","volume":"229","author":"Cleasby","year":"2016","journal-title":"J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: A randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae521","article-title":"Adrenal suppression from vamorolone and prednisone in duchenne muscular dystrophy: results from the phase 2b clinical trial","volume":"110","author":"Ahmet","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","volume-title":"Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over","year":"2025"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23793","article-title":"Why short stature is beneficial in Duchenne muscular dystrophy","volume":"48","author":"Bodor","year":"2013","journal-title":"Muscle Nerve"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12266","article-title":"Early recognition of growth abnormalities permitting early intervention","volume":"102","author":"Haymond","year":"2013","journal-title":"Acta Paediatr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1697907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:17Z","timestamp":1764911597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1697907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":41,"alternative-id":["10.3389\/fendo.2025.1697907"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1697907","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1697907"}}